ANP signaling inhibits TGF-β-induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells

Peng Li, Suzanne Oparil, Lea Novak, Xu Cao, Weibin Shi, Jason Lucas, Yiu Fai Chen

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Atrial natriuretic peptide (ANP) and transforming growth factor (TGF)-β play important counterregulatory roles in pulmonary vascular adaptation to chronic hypoxia. To define the molecular mechanism of this important interaction, we tested whether ANP-cGMP-protein kinase G (PKG) signaling inhibits TGF-β1-induced extracellular matrix (ECM) expression and defined the specific site(s) at which this molecular merging of signaling pathways occurs. Rat pulmonary arterial smooth muscle cells (PASMCs) were treated with ANP (1 μM) or cGMP (1 mM) with or without pretreatment with PKG inhibitors KT-5823 (1 μM) or Rp-8-bromo-cGMP (Rp-8-Br-cGMP 50 μM), then exposed to TGF-β1 (1 ng/ml) for 5-360 min (for pSmad nuclear translocation and protein analysis) or 24 h (for ECM mRNA expression). Nuclear translocation of pSmad2 and pSmad3 was assessed by fluorescent confocal microscopy. ANP and cGMP inhibited TGF-β1-induced pSmad2 and pSmad3 nuclear translocation and expression of periostin, osteopontin, and plasminogen activator inhibitor-1 mRNA and protein, but not TGF-β1-induced phosphorylation of Smad2 and Smad3. KT-5823 and Rp-8-Br-cGMP blocked ANP/cGMP-induced activation of PKG and inhibition of TGF-β1-stimulated nuclear translocation of pSmad2 and pSmad3 in PASMCs. These results reveal for the first time a precise site at which ANP-cGMP-PKG signaling exerts its antifibrogenic effect on the profibrogenic TGF-β1 signaling pathway: by blocking TGF-β1-induced pSmad2 and pSmad3 nuclear translocation and ECM expression in PASMCs. Blocking nuclear translocation and subsequent binding of pSmad2 and pSmad3 to TGF-β-Smad response elements in ECM genes may be responsible for the inhibitory effects of ANP on TGF-β-induced expression of ECM molecules.

Original languageEnglish (US)
Pages (from-to)390-398
Number of pages9
JournalJournal of applied physiology
Volume102
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Nuclear Matrix
Transforming Growth Factors
Atrial Natriuretic Factor
Smooth Muscle Myocytes
Extracellular Matrix
Lung
Cyclic GMP-Dependent Protein Kinases
KT 1
Messenger RNA
Osteopontin
Plasminogen Activator Inhibitor 1
Response Elements
Protein Kinase Inhibitors
Nuclear Proteins
Confocal Microscopy
Blood Vessels
Phosphorylation

All Science Journal Classification (ASJC) codes

  • Physiology
  • Physiology (medical)

Cite this

@article{c98223e4c62c4ea382ee40ceb9c827fa,
title = "ANP signaling inhibits TGF-β-induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells",
abstract = "Atrial natriuretic peptide (ANP) and transforming growth factor (TGF)-β play important counterregulatory roles in pulmonary vascular adaptation to chronic hypoxia. To define the molecular mechanism of this important interaction, we tested whether ANP-cGMP-protein kinase G (PKG) signaling inhibits TGF-β1-induced extracellular matrix (ECM) expression and defined the specific site(s) at which this molecular merging of signaling pathways occurs. Rat pulmonary arterial smooth muscle cells (PASMCs) were treated with ANP (1 μM) or cGMP (1 mM) with or without pretreatment with PKG inhibitors KT-5823 (1 μM) or Rp-8-bromo-cGMP (Rp-8-Br-cGMP 50 μM), then exposed to TGF-β1 (1 ng/ml) for 5-360 min (for pSmad nuclear translocation and protein analysis) or 24 h (for ECM mRNA expression). Nuclear translocation of pSmad2 and pSmad3 was assessed by fluorescent confocal microscopy. ANP and cGMP inhibited TGF-β1-induced pSmad2 and pSmad3 nuclear translocation and expression of periostin, osteopontin, and plasminogen activator inhibitor-1 mRNA and protein, but not TGF-β1-induced phosphorylation of Smad2 and Smad3. KT-5823 and Rp-8-Br-cGMP blocked ANP/cGMP-induced activation of PKG and inhibition of TGF-β1-stimulated nuclear translocation of pSmad2 and pSmad3 in PASMCs. These results reveal for the first time a precise site at which ANP-cGMP-PKG signaling exerts its antifibrogenic effect on the profibrogenic TGF-β1 signaling pathway: by blocking TGF-β1-induced pSmad2 and pSmad3 nuclear translocation and ECM expression in PASMCs. Blocking nuclear translocation and subsequent binding of pSmad2 and pSmad3 to TGF-β-Smad response elements in ECM genes may be responsible for the inhibitory effects of ANP on TGF-β-induced expression of ECM molecules.",
author = "Peng Li and Suzanne Oparil and Lea Novak and Xu Cao and Weibin Shi and Jason Lucas and Chen, {Yiu Fai}",
year = "2007",
month = "1",
day = "1",
doi = "10.1152/japplphysiol.00468.2006",
language = "English (US)",
volume = "102",
pages = "390--398",
journal = "Journal of Applied Physiology",
issn = "8750-7587",
publisher = "American Physiological Society",
number = "1",

}

ANP signaling inhibits TGF-β-induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells. / Li, Peng; Oparil, Suzanne; Novak, Lea; Cao, Xu; Shi, Weibin; Lucas, Jason; Chen, Yiu Fai.

In: Journal of applied physiology, Vol. 102, No. 1, 01.01.2007, p. 390-398.

Research output: Contribution to journalArticle

TY - JOUR

T1 - ANP signaling inhibits TGF-β-induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells

AU - Li, Peng

AU - Oparil, Suzanne

AU - Novak, Lea

AU - Cao, Xu

AU - Shi, Weibin

AU - Lucas, Jason

AU - Chen, Yiu Fai

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Atrial natriuretic peptide (ANP) and transforming growth factor (TGF)-β play important counterregulatory roles in pulmonary vascular adaptation to chronic hypoxia. To define the molecular mechanism of this important interaction, we tested whether ANP-cGMP-protein kinase G (PKG) signaling inhibits TGF-β1-induced extracellular matrix (ECM) expression and defined the specific site(s) at which this molecular merging of signaling pathways occurs. Rat pulmonary arterial smooth muscle cells (PASMCs) were treated with ANP (1 μM) or cGMP (1 mM) with or without pretreatment with PKG inhibitors KT-5823 (1 μM) or Rp-8-bromo-cGMP (Rp-8-Br-cGMP 50 μM), then exposed to TGF-β1 (1 ng/ml) for 5-360 min (for pSmad nuclear translocation and protein analysis) or 24 h (for ECM mRNA expression). Nuclear translocation of pSmad2 and pSmad3 was assessed by fluorescent confocal microscopy. ANP and cGMP inhibited TGF-β1-induced pSmad2 and pSmad3 nuclear translocation and expression of periostin, osteopontin, and plasminogen activator inhibitor-1 mRNA and protein, but not TGF-β1-induced phosphorylation of Smad2 and Smad3. KT-5823 and Rp-8-Br-cGMP blocked ANP/cGMP-induced activation of PKG and inhibition of TGF-β1-stimulated nuclear translocation of pSmad2 and pSmad3 in PASMCs. These results reveal for the first time a precise site at which ANP-cGMP-PKG signaling exerts its antifibrogenic effect on the profibrogenic TGF-β1 signaling pathway: by blocking TGF-β1-induced pSmad2 and pSmad3 nuclear translocation and ECM expression in PASMCs. Blocking nuclear translocation and subsequent binding of pSmad2 and pSmad3 to TGF-β-Smad response elements in ECM genes may be responsible for the inhibitory effects of ANP on TGF-β-induced expression of ECM molecules.

AB - Atrial natriuretic peptide (ANP) and transforming growth factor (TGF)-β play important counterregulatory roles in pulmonary vascular adaptation to chronic hypoxia. To define the molecular mechanism of this important interaction, we tested whether ANP-cGMP-protein kinase G (PKG) signaling inhibits TGF-β1-induced extracellular matrix (ECM) expression and defined the specific site(s) at which this molecular merging of signaling pathways occurs. Rat pulmonary arterial smooth muscle cells (PASMCs) were treated with ANP (1 μM) or cGMP (1 mM) with or without pretreatment with PKG inhibitors KT-5823 (1 μM) or Rp-8-bromo-cGMP (Rp-8-Br-cGMP 50 μM), then exposed to TGF-β1 (1 ng/ml) for 5-360 min (for pSmad nuclear translocation and protein analysis) or 24 h (for ECM mRNA expression). Nuclear translocation of pSmad2 and pSmad3 was assessed by fluorescent confocal microscopy. ANP and cGMP inhibited TGF-β1-induced pSmad2 and pSmad3 nuclear translocation and expression of periostin, osteopontin, and plasminogen activator inhibitor-1 mRNA and protein, but not TGF-β1-induced phosphorylation of Smad2 and Smad3. KT-5823 and Rp-8-Br-cGMP blocked ANP/cGMP-induced activation of PKG and inhibition of TGF-β1-stimulated nuclear translocation of pSmad2 and pSmad3 in PASMCs. These results reveal for the first time a precise site at which ANP-cGMP-PKG signaling exerts its antifibrogenic effect on the profibrogenic TGF-β1 signaling pathway: by blocking TGF-β1-induced pSmad2 and pSmad3 nuclear translocation and ECM expression in PASMCs. Blocking nuclear translocation and subsequent binding of pSmad2 and pSmad3 to TGF-β-Smad response elements in ECM genes may be responsible for the inhibitory effects of ANP on TGF-β-induced expression of ECM molecules.

UR - http://www.scopus.com/inward/record.url?scp=33846129453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846129453&partnerID=8YFLogxK

U2 - 10.1152/japplphysiol.00468.2006

DO - 10.1152/japplphysiol.00468.2006

M3 - Article

C2 - 17038494

AN - SCOPUS:33846129453

VL - 102

SP - 390

EP - 398

JO - Journal of Applied Physiology

JF - Journal of Applied Physiology

SN - 8750-7587

IS - 1

ER -